Impact of autoimmune diseases on outcome of patients with early breast cancer

Carmen Criscitiello, Vincenzo Bagnardi, Angela Esposito, Lucia Gelao, Barbara Santillo, Giulia Viale, Nicole Rotmensz, Aron Goldhirsch, Giuseppe Curigliano

Research output: Contribution to journalArticlepeer-review


Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and vasculitis. For each patient in the study group, we matched 2 patients. The events to determine overall survival (OS) and disease free survival (DFS) were identified from follow-up data. We identified 279 (1.62%) patients with early breast cancer and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for the control group (p = 0.011). In patients with ER positive/HER2 negative subtype a worse OS was observed in the study group when compared to the control group (p = 0.0046); this difference remained statistically significant when the analysis was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is associated with worse survival.

Original languageEnglish
Pages (from-to)51184-51192
Number of pages9
Issue number32
Publication statusPublished - Aug 1 2016


  • Autoimmunity
  • Clinical outcome
  • Early breast cancer
  • Endocrine therapy
  • Immunology

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Impact of autoimmune diseases on outcome of patients with early breast cancer'. Together they form a unique fingerprint.

Cite this